13F Holdings
中文EN

ANVS Annovis Bio, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1477845 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-107.9%
TTM EPS YoY-8.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-455.9%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets340.5%
Debt / equity—
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.08x
Accruals ratio36.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0$0$0$0
R&D expense$25.22M$20.00M$38.79M$16.52M$8.48M
SG&A expense$4.48M$6.70M$6.24M$9.00M$6.06M
Operating income-$29.70M-$26.69M-$45.04M-$25.51M-$14.54M
Pretax income——-$56.20M-$25.33M-$14.49M
Income tax$0————
Net income-$28.85M-$24.59M-$56.20M-$25.33M-$14.49M
EPS (basic)-1.40-2.02-6.23-3.10-1.90
EPS (diluted)-1.40-2.31-6.23-3.10-1.90
Weighted avg. shares (diluted)20.55M12.24M9.02M8.16M7.63M
Balance sheet
Cash & equivalents$19.53M$10.55M$5.75M$28.38M$45.69M
Current assets——$10.21M$36.02M$46.00M
Total assets$21.08M$13.93M$10.21M$36.02M$46.00M
Current liabilities$3.64M$3.88M$4.28M$7.70M$1.51M
Total liabilities$4.23M$4.62M$17.96M$7.70M$1.51M
Shareholders' equity$16.85M$9.31M-$7.75M$28.32M$44.49M
Shares outstanding27.20M14.14M10.52M8.16M8.10M
Cash flow statement
Operating cash flow-$25.62M-$21.89M-$39.97M-$17.31M-$9.13M
Financing cash flow$34.60M$26.69M$17.34M$4,613$46.74M
Stock-based compensation$1.80M$3.84M$4.63M$9.15M$4.70M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.